Mesothelium has been shown to have increased expression of VISTA and a phase I clinical trial (NCT02812875) is currently underway to evaluate the efficacy of an antagonist against VISTA in individuals with advanced lymphomas or solid tumors (137, 138). This evidence concerns the gene VSIR and lymphoma.